View Older Stories View More Recent Stories

Jan 31, 2022 09:00AM Gilead Sciences (GILD) Announces U.S. FDA Approves New Label Update for CAR T-Cell Therapy Yescarta Showing Prophylactic Steriod Use Improves Management of Cytokine Release Syndrome
Jan 31, 2022 09:00AM U.S. FDA Approves New Label Update for CAR T-Cell Therapy Yescarta® Showing Prophylactic Steriod Use Improves Management of Cytokine Release Syndrome
Jan 26, 2022 05:47AM Gilead Sciences (GILD) Announces FDA Clinical Hold on Studies Evaluating Magrolimab in Combination With Azacitidine
Jan 25, 2022 06:52PM Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination With Azacitidine
Jan 24, 2022 05:55AM Gilead Sciences (GILD) Announces FDA Approval of Veklury for Treatment of Non-Hospitalized Patients at High Risk for COVID-19
Jan 21, 2022 06:24PM FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression
Jan 18, 2022 04:05PM Gilead Sciences to Release Fourth Quarter & Full Year 2021 Financial Results on Tuesday, February 1, 2022
Jan 10, 2022 08:31AM Gilead Sciences (GILD) Enters Clinical Collaboration with Merck (MRK) to Evaluate Trodelvy in Combination With KEYTRUDA
Jan 10, 2022 08:30AM Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy® in Combination With KEYTRUDA® in First-Line Metastatic Non-Small Cell Lung Cancer
Dec 22, 2021 05:17PM Gilead Sciences (GILD) Announces NEJM Publication of Data Demonstrating Veklury (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients With COVID-19
Dec 22, 2021 05:08PM Gilead Announces New England Journal of Medicine Publication of Data Demonstrating Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients With COVID-19
Dec 22, 2021 05:39AM Gilead Sciences (GILD) Announces Clinical Hold on Studies Evaluating Injectable Lenacapavir for HIV Treatment and Prevention Due to Vial Quality Concerns
Dec 21, 2021 07:12PM Gilead Announces Clinical Hold on Studies Evaluating Injectable Lenacapavir for HIV Treatment and Prevention Due to Vial Quality Concerns
Dec 21, 2021 04:35PM Gilead and Arcus Biosciences Complete Closing of Option Exercise for Three Clinical-stage Programs and New Research Collaboration
Dec 21, 2021 04:35PM Gilead and Arcus Biosciences Complete Closing of Option Exercise for Three Clinical-Stage Programs and New Research Collaboration
Dec 21, 2021 04:05PM Gilead Sciences to Present at Upcoming Investor Conference
Dec 21, 2021 05:09AM Gilead Sciences (GILD) Granted Expanded Indication for Veklury in Europe for Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression
Dec 21, 2021 04:00AM European Commission Expands Indication for Veklury (Remdesivir) for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression
Dec 16, 2021 06:00PM Daiichi Sankyo Authorizes the First YESCARTA® (Axicabtagene Ciloleucel) CAR T-cell Therapy Treatment Site in Japan
Dec 13, 2021 02:49PM Gilead Sciences (GILD) Announces Yescarta ZUMA-12 Study Demonstrates 78% Complete Response Rate as Part of First-Line Treatment in Newly Diagnosed High-Risk Large B-Cell Lymphoma
Dec 13, 2021 02:45PM Yescarta® ZUMA-12 Study Demonstrates 78% Complete Response Rate as Part of First-Line Treatment in Newly Diagnosed High-Risk Large B-Cell Lymphoma
Dec 13, 2021 05:20AM Gilead's (GILD) Kite Announces Yescarta Demonstrates Durable Two-Year Clinical Benefit in Adults With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Including Follicular Lymphoma
Dec 11, 2021 10:00AM Yescarta® Demonstrates Durable Two-Year Clinical Benefit in Adults With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Including Follicular Lymphoma
Dec 11, 2021 09:00AM Yescarta® Is First CAR T-cell Therapy to Report Five-Year Survival Data From Pivotal Study Showing Durable Long-Term Survival in Patients With Refractory Large B-cell Lymphoma
Dec 11, 2021 08:30AM Yescarta® CAR T-Cell Therapy Quadruples Median Event-Free Survival Duration Over Standard of Care in Second-Line Relapsed or Refractory Large B-Cell Lymphoma
Dec 10, 2021 08:00AM Trodelvy® Demonstrates Clinical Benefit for Black Patients Consistent with Full Metastatic Triple-Negative Breast Cancer Population in ASCENT Study
Nov 29, 2021 08:30AM Gilead’s Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Highlighted With New Data at SABCS
Nov 23, 2021 08:31AM Gilead Sciences (GILD) Trodelvy Granted European Commission Marketing Authorization for Treatment of Metastatic TNBC in Second Line
Nov 23, 2021 08:30AM Trodelvy® (sacituzumab govitecan) Granted European Commission Marketing Authorization for Treatment of Metastatic Triple-Negative Breast Cancer in Second Line
Nov 19, 2021 08:01AM Gilead Sciences (GILD) Submits BLA to FDA for Bulevirtide, an Investigational Treatment for People Living With Chronic Hepatitis Delta
Nov 19, 2021 08:00AM Gilead Submits Biologics License Application to U.S. Food and Drug Administration for Bulevirtide, an Investigational Treatment for People Living With Chronic Hepatitis Delta
Nov 18, 2021 04:05PM Gilead Sciences to Present at Upcoming Investor Conference
Nov 18, 2021 07:03AM Gilead (GILD) Exercises Options to Three Arcus Biosciences (RCUS) Clinical-stage Programs and Adds Research Collaboration
Nov 18, 2021 07:00AM Gilead Exercises Options to Three Arcus Biosciences Clinical-Stage Programs and Adds Research Collaboration
Nov 18, 2021 07:00AM Gilead Exercises Options to Three Arcus Biosciences Clinical-stage Programs and Adds Research Collaboration
Nov 11, 2021 05:38AM Gilead Sciences (GILD) and Everest Medicine Announces Phase 2b Study of Sacituzumab Govitecan Meets Primary Overall Response Rate Endpoint
Nov 10, 2021 07:00PM Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-Negative Breast Cancer Meets Primary Overall Respon
Nov 9, 2021 10:00AM Gilead to Present Data From Liver Disease Development Programs at The Liver Meeting®
Nov 4, 2021 09:23AM Gilead Sciences (GILD) and Kite Interim Data from ANCHOR Study of KUR-502
Nov 4, 2021 09:23AM Gilead and Kite Oncology Demonstrate Broad Leadership in Cell Therapy and Expanding Blood Cancer Pipeline
Oct 29, 2021 07:31AM Gilead Sciences's (GILD) Biktarvy Demonstrate Consistent Efficacy Profile in Real-World Setting
Oct 29, 2021 07:30AM Clinical and Patient-Reported Outcomes in People Living With HIV on Biktarvy® in Observational BICSTaR Study Demonstrate Consistent Efficacy Profile in Real-World Setting
Oct 28, 2021 04:10PM Gilead Announces Clinical Trial Collaboration With Merck to Evaluate Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) in Patients With First-Line Metastatic Tripl
Oct 26, 2021 06:47AM Gilead (GILD), Merck (MRK) Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppr
Oct 26, 2021 06:45AM Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adul
Oct 21, 2021 07:37AM Gilead Sciences (GILD) Presents Long-Term Switch Data Reinforcing Biktarvy® as a Treatment Option for a Broad Range of People Living With HIV
Oct 21, 2021 07:37AM Gilead Presents Long-Term Switch Data Reinforcing Biktarvy® as a Treatment Option for a Broad Range of People Living With HIV
Oct 19, 2021 08:30AM Gilead Sciences Announces Veklury® Donations to Help Address the Ongoing COVID-19 Crisis in Indonesia and Armenia
Oct 18, 2021 07:31AM Gilead Sciences (GILD) Announces FDA Approval of Expanded Indication of Gilead’s Biktarvy for Treatment of HIV-1 in Pediatric Population
Oct 18, 2021 07:30AM U.S. Food and Drug Administration Approves Expanded Indication of Gilead’s Biktarvy® for Treatment of HIV-1 in Pediatric Populations
View More Recent Stories View Older Stories